Skip to content
Catalyst

PapersPMID:21939549

Preliminary examination of the efficacy and safety of a standardized chamomile extract for chronic primary insomnia: a randomized placebo-controlled pilot study.

BMC complementary and alternative medicine2011The record ↗

  1. Finding, moderate evidenceno difference foundBeck Depression Inventory (BDI) total score

No finding here moved its endpoint.

What did not

1 findingHow to read these marks →
  • “Chamomile had no significant effect on differences in either the BDI (p = 0.60) or the trait subscale of the STAI (p = 0.45).”
    Study
    RCT
    Duration
    4 weeks
    Dose studied
    270 mg twice daily (540 mg/day), one dose between lunch and dinner and one about an hour before bed
    Population
    adults aged 18-65 with DSM-IV chronic primary insomnia of at least 6 months, current mood or anxiety disorder excluded

Study record

Design
randomised controlled trial
Species
human
Population
Adults aged 18 to 65 with DSM-IV primary insomnia for at least 6 months
Participants
34
Comparator
placebo
Duration
28 days
Endpoints measured
16